Your Messages Inbox
Your Article Summary
See Latest Articles
Roche announced that two-year data from the LITHE study demonstrated that ACTEMRA continued to inhibit the progression of structural damage to joints in patients with rheumatoid arthritis. The study also showed that patients receiving ACTEMRA experienced improved physical function, as measured by the Health Assessment Questionnaire Disability Index scores. The LITHE study is the fifth international Phase III study in the extensive ACTEMRA clinical development program to successfully meet its primary endpoints in patients with moderately to severely active RA.
Today in Physician/Patient Trends...keeping you current
Receive free subspecialty "5-minute updates" via email
How important is intestinal cytochrome P450 3A metabolism
Trends in Pharmacological Sciences, 10/14/09
Urinary Diversion Trends at a High Volume, Single American Tertiary Care Center
The Journal of Urology, 11/02/09
Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds
British Journal of Clinical Pharmacology, 11/02/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Myriad, 10/16/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Article Search
Sponsor